How should a patient with a positive rectal swab screening for multidrug-resistant Escherichia coli be managed?

Management of MDR E. coli Rectal Colonization

Do not treat asymptomatic colonization with antibiotics, but implement contact precautions and document the colonization status for future perioperative planning. 1

Immediate Actions

Infection Control Measures

• Implement contact precautions to prevent transmission to other patients
• Place patient in single room when possible or cohort with other MDRO carriers
• Use dedicated equipment for the colonized patient
• Ensure strict hand hygiene and use of gloves and gowns for all patient contact

Clinical Assessment

Distinguish colonization from infection immediately:

• Colonization = positive culture WITHOUT clinical signs/symptoms of infection
• If patient has fever, leukocytosis, or organ-specific symptoms → this is infection, not colonization, and requires treatment
• Do not treat asymptomatic bacteriuria or colonization 2

Key Management Principle

Routine decolonization is NOT recommended for MDR Gram-negative bacteria carriers, including extended-spectrum cephalosporin-resistant Enterobacterales (which includes most MDR E. coli). 1 The evidence for decolonization efficacy is insufficient and may promote further resistance development.

Documentation and Future Planning

Essential Documentation

Document the following in the patient's medical record:

• Date of positive screening
• Specific resistance pattern (obtain full antibiogram)
• Whether patient has ESBL-producing E. coli or other specific resistance mechanisms
• Any fluoroquinolone resistance

Perioperative Implications

If the patient requires future surgery, colonization status critically affects antibiotic prophylaxis:

For patients with MDR E. coli colonization undergoing surgery 3:

First-line options (choose based on susceptibility):

• Ampicillin/sulbactam 3g IV (redose every 2-4 hours intraoperatively)
• Piperacillin/tazobactam 3.375-4.5g IV (redose every 2-4 hours)
• Gentamicin 5 mg/kg IV (avoid if renal dysfunction or other nephrotoxic drugs)

Alternative options:

• Ciprofloxacin 400mg IV (only if fluoroquinolone-susceptible)
• Ertapenem 1g IV (reserve for when other options unavailable due to stewardship concerns)

Critical surgical considerations:

• Preoperative colonization with ESBL-producing E. coli significantly increases surgical site infection risk (adjusted OR 16.53 in orthopedic surgery) 4
• Standard prophylaxis will fail in colonized patients
• Tailor prophylaxis to the documented susceptibility pattern from the screening culture

Special Populations

Transrectal Procedures (e.g., prostate biopsy)

If patient needs transrectal ultrasound-guided prostate biopsy 3, 5:

• Standard fluoroquinolone prophylaxis will fail if fluoroquinolone-resistant
• Consider alternatives: gentamicin 3-5 mg/kg IV, cotrimoxazole, or fosfomycin based on susceptibilities
• Screening reduces post-biopsy sepsis risk by approximately 3.6% 5

Immunocompromised Patients

• Higher risk of progression from colonization to infection 1
• Monitor more closely for signs of infection
• Consider more aggressive infection control measures
• Current evidence insufficient to recommend prophylactic decolonization even in this population

Common Pitfalls to Avoid

1. Do not prescribe antibiotics for asymptomatic colonization - this promotes further resistance without clinical benefit
2. Do not assume standard surgical prophylaxis will work - must adjust based on documented resistance pattern
3. Do not rely on risk factor questionnaires alone to predict resistance patterns - actual culture results are necessary 6
4. Do not forget to screen groin in addition to rectum if concerned about other MDROs like Candida auris 7, though for E. coli, rectal swab is the primary site

Surveillance and Follow-up

• No routine repeat screening needed unless patient develops infection or requires surgery
• Colonization can persist for months to years
• Prevalence of MDR E. coli colonization ranges from 4-32% depending on population and region 4, 6, 8
• In hospitalized patients with gastrointestinal illness, prevalence approaches 99% in some settings 8

When to Consult

• Infectious Disease consultation if patient develops clinical infection
• Infection Prevention for outbreak investigation if multiple cases identified
• Surgical team well in advance of any planned procedures to plan appropriate prophylaxis